KaloBios Pharmaceuticals Raises $20 Million in Private Equity

KaloBios Pharmaceuticals, a privately-held emerging therapeutic antibody company, announced the completion of its Series B financing round of $20 million. Lead investors MPM Capital and GBS Venture Partners were joined by Lotus BioScience Ventures and existing investors, Sofinnova Ventures, Alloy Ventures, 5AM Ventures and Singapore BioInnovations Pte. The proceeds from this round will be used to build a clinical development team and progress two lead antibodies into clinical evaluation. Dennis Henner, General Partner at MPM Capital and Brigitte Smith at GBS will join the Board of Directors.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19400320&full=1)